CHATSWORTH, Calif., Feb. 3, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), will release its fourth quarter and year-end 2009 financial results after the close of trading on Monday, March 1, 2010. IRIS management will also host a conference call and webcast that day at 4:30 P.M. Eastern Time, to discuss the fourth quarter results, as well as provide a general business update, including a progress report on its NADiA® ProsVue™ ultra sensitive prostate-specific antigen diagnostic assay and its iChem®VELOCITY™ urine chemistry analyzer new product initiatives.
Date: Monday, March 1, 2010
Time: 4:30 PM ET
To participate in the teleconference, please dial (10 min. before conference is scheduled to begin):
Domestic toll-free: 1- 877- 870 - 9220
International: + 973- 638 - 3437
Listen via Internet: http://proiris.com
or
http://investor.shareholder.com/media/eventdetail.cfm?eventid=77495&CompanyID=ABEA-2RC4AZ&e=1&mediaKey=0F059E45A57CA28895D6144DD88C64FA
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=40832&k=9AE6CA40
If you are unable to participate during the live conference call and webcast, the conference call audio cast will be archived and available for replay in the Investor Relations section of the Company's website at http://www.proiris.com for approximately 90 days.
About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,400 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA®, platform, with applications in oncology and infectious disease. For more information visit www.proiris.com.